Emerging scientific inquiry is illuminating a surprising potential advantage associated with a class of widely prescribed medications, originally developed for managing type 2 diabetes and facilitating weight loss. These pharmaceuticals, known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are now being investigated for a possible role in mitigating the risk of developing epilepsy. The preliminary findings, published on December 10, 2025, in the esteemed medical journal Neurology, a publication of the American Academy of Neurology, suggest a correlation between the utilization of these drugs and a diminished likelihood of experiencing this neurological condition.
It is crucial to underscore that this research, in its current stage, establishes an association rather than definitive causation. The study does not assert that GLP-1 RAs directly prevent epilepsy, but rather observes a pattern that warrants further investigation. This distinction is vital for interpreting the scientific data accurately and avoiding premature conclusions.
The implications of these initial observations are particularly significant when considering the existing health profiles of individuals with diabetes. As noted by Dr. Edy Kornelius, MD, PhD, a researcher affiliated with Chung Shan Medical University in Taichung, Taiwan, and lead author of the study, individuals diagnosed with diabetes often face an elevated predisposition to developing epilepsy later in life. The potential for these medications to offer a protective effect against such a debilitating condition is therefore a compelling area for continued exploration. Epilepsy, he elaborated, carries a multifaceted burden, impacting individuals physically, psychologically, and socially, and the current therapeutic options do not prove effective for everyone, making the discovery of novel risk-reduction strategies a critical endeavor.
To meticulously examine this potential link, the research team embarked on a comprehensive analysis of data drawn from a substantial health database within the United States. The study population comprised adults diagnosed with type 2 diabetes who had initiated treatment with either a GLP-1 RA or an alternative class of diabetes medication known as dipeptidyl peptidase-4 (DPP-4) inhibitors, often referred to by their generic names or as "gliptins." A fundamental prerequisite for inclusion in the study was that participants had no prior history or diagnosis of epilepsy or seizures. The specific GLP-1 RA medications included in the analysis were dulaglutide, liraglutide, and semaglutide, all of which have gained widespread clinical use.
The retrospective analysis encompassed a cohort of 452,766 individuals, with an average age of 61 years at the commencement of the observation period. This large group was evenly divided, with precisely half of the participants being prescribed GLP-1 RAs and the other half receiving DPP-4 inhibitors. Each participant was meticulously monitored for a minimum duration of five years to allow for the emergence of any potential health events, including the development of epilepsy. Over the course of this extended follow-up, the data revealed that 1,670 individuals utilizing GLP-1 medications subsequently developed epilepsy, representing an incidence rate of 2.35%. In comparison, among those taking DPP-4 inhibitors, 1,886 individuals were diagnosed with epilepsy, equating to an incidence of 2.41%.
Following a rigorous statistical adjustment process, designed to account for a spectrum of confounding factors that could independently influence epilepsy risk, a discernible trend emerged. These adjustments considered variables such as age, the presence of hypertension, and pre-existing cardiovascular disease, among other health conditions. After these statistical controls were applied, the analysis indicated that individuals treated with GLP-1 RAs exhibited a statistically significant, albeit modest, reduction in their likelihood of developing epilepsy compared to their counterparts receiving DPP-4 inhibitors. Specifically, the adjusted results pointed to a 16% lower risk of epilepsy among the GLP-1 RA users.
Further granular examination of the data at the individual drug level within the GLP-1 RA class revealed that semaglutide was associated with the most pronounced effect in terms of reducing epilepsy risk. This observation adds another layer of detail to the emerging picture and suggests that specific molecular targets or mechanisms within this drug class might play a more prominent role.
Dr. Kornelius reiterated that while these findings are encouraging and contribute to the growing body of evidence supporting the broader neurological benefits of GLP-1 RAs beyond their primary metabolic functions, further rigorous research is indispensable. He emphasized that these results should not be interpreted as an indictment of DPP-4 inhibitors, which remain valuable therapeutic agents, nor as a definitive declaration of the neuroprotective superiority of GLP-1 RAs. The current study highlights a potential association that requires substantiation through different research methodologies.
The researchers also meticulously detailed several important considerations and inherent limitations of their study. Notably, tirzepatide, a more recently developed medication that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, was not included in this analysis. This exclusion was due to its availability timeline, which fell outside the established study period. Consequently, the findings presented may not be directly generalizable to individuals using tirzepatide, necessitating separate investigations into its potential neurological effects.
Beyond the limitations inherent in the retrospective, observational design of the study, the research team acknowledged the absence of data on several other critical factors that could potentially influence an individual’s susceptibility to epilepsy. These omitted variables include a family history of neurological disorders, genetic predispositions that might confer a higher risk, and patterns of alcohol consumption, all of which can play a role in seizure disorders. Furthermore, the researchers pointed out that socioeconomic factors, such as the cost of medications, insurance coverage mandates, and the perceived severity of an individual’s diabetes, might have inadvertently influenced the initial choice of prescribed medication. These unmeasured variables could have introduced subtle differences between the study groups that were not fully accounted for in the statistical models, potentially affecting the observed associations.
The research initiative was made possible through the financial and institutional support provided by Chung Shan Medical University Hospital, underscoring the collaborative nature of scientific discovery and the commitment of academic institutions to advancing medical knowledge.
About the Author
